新型肿瘤选择性富硼化合物的开发作为硼中子俘获疗法(BNCT)的潜在药物代表了放射疗法癌症治疗的一个非常重要的领域。在这里,我们报告了两种有前途的化合物的设计和合成,它们结合了间碳硼烷(一种水溶性单糖)和连接单元(即甘氨酸或乙二胺),可轻松与带有游离氨基或羧酸基团的各种肿瘤选择性生物分子偶联。在这项工作中,包括使用两种选定的生物分子(香豆素衍生物和叶酸)的偶联实验。该方法中每个组件的任务都经过精心选择:碳硼烷部分提供十个硼原子,与目前BNCT中使用的l-硼苯丙氨酸( l -BPA)相比,硼含量增加了十倍;糖部分补偿了碳硼烷的疏水特性;根据所选择的生物分子,连接单元充当肿瘤选择性成分和富硼部分之间的连接;相应的肿瘤选择性生物分子提供了必要的选择性。这种方法使得开发一种模块化且可行的策略来合成易于获得的富硼剂成为可能,这些富硼剂具有优化的性能,可用于 BNCT 的潜在应用。
One-pot synthesis of an indole-substituted 7,8-dicarba-nido-dodecahydroundecaborate(−1)
作者:W. Neumann、R. Frank、E. Hey-Hawkins
DOI:10.1039/c4dt03218g
日期:——
Carbaboranes are increasingly used as pharmacophores to replace phenyl substituents in established drug molecules. In contrast to traditional organic chemistry, elaborate procedures to introduce functionality frequently fail in the case of carbaboranes and their chemistry is often hampered by degradation of the cluster. Herein, the development of a one-pot synthesis of a water-soluble N-nido-dicarbaborato
Asymmetric hydrogenation with the use of chiral carborane amidophosphite derivatives in supercritical carbon dioxide and CH2Cl2
作者:S. E. Lyubimov、V. A. Ol’shevskaya、P. V. Petrovskii、E. A. Rastorguev、T. A. Verbitskaya、V. N. Kalinin、V. A. Davankov
DOI:10.1007/s11172-010-0321-y
日期:2010.9
New chiral carborane-containing amidophosphites containing the BINOL fragment (BINOL stands for 2,2′-dihydroxy-1,1′-binaphthyl) have been synthesized. The study of efficiency of these compounds as ligands in the Rh-catalyzed asymmetric hydrogenation of enamides in supercritical carbon dioxide (scCO2) and CH2Cl2 showed that enantioselectivity of the process is considerably higher in scCO2.